Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, review timing and choice of first-line antiretroviral therapy in this unique program with a didactic video module and several case-based vignettes in which you are invited to help manage the patient.
Upon completion of this activity, participants should be able to:
TURQUOISE-I: High SVR12 Rates With ABT-450/Ritonavir/Ombitasvir + Dasabuvir + RBV in HIV/Genotype 1 HCV–Coinfected Patients on Stable Atazanavir- or Raltegravir-Based ART
Sizing Up the Newest Integrase Inhibitor–Based Single-Tablet Regimen
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients
To Switch or Not to Switch: Management of First-line Boosted PI Virologic Failure
PHOTON-2: Sofosbuvir + Ribavirin Yields High SVR12 Rates in Patients Coinfected With HIV and Genotypes 1-4 HCV
Clinical Care Options, LLC. All Rights Reserved.